1Bryant LD, Green JM, Newison J. Prenatal screening for Down's syndrome:Some psychosocial implications of a' screening for all'policy. Public Health, 2001,115(5):356-358.
2Holding S. Current state of screening for Down's syndrome.Ann Clin Biochem, 2002,39(Ptl ):1-11.
3Baviera G, Corrado F, Carbone C. Prostate-specific antigen in prenatal screening for Down's syndrome. Eur J Obstet Gynecol Reprod Biol, 2001,96(2):238.
4Knight GJ, Palomaki GE, Neveux LM, et al. Clinical validation of new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. J Med Screen, 2001,8( 1 ):2-7.
5Niemimaa M, Suonpaa M, Perheetupa A, et al. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland. Eur J Hum Genet, 2001,9(6):101-108.
6Hsu JJ, Spencer K, Aitken DA, et al. Urinanry free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy. Prenat Diagn, 1999,19(2):146-158.
7Hallaban TW, Krantz DA, Tului L, et al. Comparison of urinanry free beta (hCG) and beta-core (hCG) in prenatal screening for chromosomal abnormalities. Prenat Diagn, 1998,18:893-900.
8Maymon R, Dreazen E, Weinraub Z, et al. Screening for Down's syndrome at week 10-14 by measuring fetal nuchal translucency thickness. Harefuah, 1999,137(9):353-357.
9Malone FD, Berkowitz RL, Canick JA, et al. First-trimester screening for aneuploidy: Resear or standard of care? Am J Obstet Gynaecol, 2000,182 ( 3 ) :490-496.
10Rozenberg P, Malagrida L, Cuckle H, et al. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14 (+1)-17 (+0) weeks: a prospective study. Hum Reprod, 2002,17(4):1093-1098.
